{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:37:17Z","timestamp":1790789837958,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      Imaging is used for lymphoma detection, Ann Arbor\/Lugano staging, and treatment response assessment. [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT should be used for most lymphomas, including Hodgkin lymphoma, aggressive\/high-grade Non-Hodgkin lymphomas (NHL) such as diffuse large B-cell lymphoma, and many indolent\/low-grade NHLs such as follicular lymphoma. Apart from these routinely FDG-avid lymphomas, some indolent NHLs, such as marginal zone lymphoma, are variably FDG-avid; here, [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT is an alternative to contrast-enhanced CT at baseline and may be used for treatment response assessment if the lymphoma was FDG-avid at baseline. Only small lymphocytic lymphoma\/chronic lymphocytic leukemia (SLL\/CLL) should exclusively undergo CT at baseline and follow-up unless transformation to high-grade lymphoma is suspected. While [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET\/CT is sufficient to rule out bone marrow involvement in Hodgkin lymphoma, biopsy may be needed in other lymphomas. The 5-point (Deauville) score for [\n                      <jats:sup>18<\/jats:sup>\n                      F]FDG PET that uses the liver and blood pool uptake as references should be used to assess treatment response in all FDG-avid lymphomas; post-treatment FDG uptake \u2264 liver uptake is considered complete response. In all other lymphomas, CT should be used to determine changes in lesion size; for complete response, resolution of all extranodal manifestations, and for lymph nodes, long-axis decrease to \u2264\u20091.5\u2009cm are required.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:italic>[<\/jats:italic>\n                            <jats:sup>\n                              <jats:italic>18<\/jats:italic>\n                            <\/jats:sup>\n                            <jats:italic>F]FDG-PET\/CT and contrast-enhanced CT are used to stage lymphoma depending on type.<\/jats:italic>\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:italic>Imaging is required for staging, and biopsies may be required to rule out bone marrow involvement.<\/jats:italic>\n                          <\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>\n                            <jats:italic>For treatment response assessment, the 5-PS (Deauville) score should be used; in a few indolent types, CT is used to determine changes in lesion size.<\/jats:italic>\n                          <\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00330-024-11213-5","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T20:04:52Z","timestamp":1735848292000},"page":"4387-4394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["ESR Essentials: imaging of lymphoma\u2014practice recommendations by the European Society of Oncologic Imaging"],"prefix":"10.1007","volume":"35","author":[{"given":"Doris","family":"Leithner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin","family":"D\u2019Anastasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Peter","family":"Schlemmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Winkelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang G.","family":"Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens C.","family":"Cyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Cioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evis","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8786-8686","authenticated-orcid":false,"given":"Marius E.","family":"Mayerhoefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"11213_CR1","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36:1720\u20131748","journal-title":"Leukemia"},{"key":"11213_CR2","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.6004\/jnccn.2023.0057","volume":"21","author":"AD Zelenetz","year":"2023","unstructured":"Zelenetz AD, Gordon LI, Abramson JS et al (2023) NCCN guidelines\u00ae insights: B-cell lymphomas, version 6.2023. J Natl Compr Canc Netw 21:1118\u20131131","journal-title":"J Natl Compr Canc Netw"},{"key":"11213_CR3","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059\u20133068","journal-title":"J Clin Oncol"},{"key":"11213_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2967\/jnumed.122.264106","volume":"64","author":"F Ricard","year":"2023","unstructured":"Ricard F, Cheson B, Barrington S et al (2023) Application of the Lugano classification for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the PRoLoG Consensus Initiative (Part 1-clinical). J Nucl Med 64:102\u2013108","journal-title":"J Nucl Med"},{"key":"11213_CR5","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3324\/haematol.2019.240564","volume":"105","author":"Y Wang","year":"2020","unstructured":"Wang Y, Rabe KG, Bold MS et al (2020) The role of [18F]FDG-PET in detecting Richter\u2019s transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. Haematologica 105:2675\u20132678","journal-title":"Haematologica"},{"key":"11213_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1148\/rg.2015140145","volume":"35","author":"S Toledano-Massiah","year":"2015","unstructured":"Toledano-Massiah S, Luciani A, Itti E et al (2015) Whole-body diffusion-weighted imaging in Hodgkin lymphoma and diffuse large B-cell lymphoma. Radiographics 35:747\u2013764","journal-title":"Radiographics"},{"key":"11213_CR7","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ejrad.2015.12.006","volume":"85","author":"D Albano","year":"2014","unstructured":"Albano D, Patti C, La Grutta L et al (2014) Comparison between whole-body MRI with diffusion-weighted imaging and PET\/CT in staging newly diagnosed FDG-avid lymphomas. Eur J Radiol 85:313\u2013318","journal-title":"Eur J Radiol"},{"key":"11213_CR8","doi-asserted-by":"publisher","first-page":"2984","DOI":"10.1158\/1078-0432.CCR-13-3355","volume":"20","author":"ME Mayerhoefer","year":"2014","unstructured":"Mayerhoefer ME, Karanikas G, Kletter K et al (2014) Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients. Clin Cancer Res 20:2984\u20132993","journal-title":"Clin Cancer Res"},{"key":"11213_CR9","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s00277-022-04789-9","volume":"101","author":"T Husby","year":"2022","unstructured":"Husby T, Johansen H, Bogsrud T et al (2022) A comparison of FDG PET\/MR and PET\/CT for staging, response assessment, and prognostic imaging biomarkers in lymphoma. Ann Hematol 101:1077\u20131088","journal-title":"Ann Hematol"},{"key":"11213_CR10","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00259-017-3635-2","volume":"44","author":"J Kirchner","year":"2017","unstructured":"Kirchner J, Deuschl C, Grueneisen J et al (2017) 18F-FDG PET\/MRI in patients suffering from lymphoma: how much MRI information is really needed? Eur J Nucl Med Mol Imaging 44:1005\u20131013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11213_CR11","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/RLI.0000000000000218","volume":"51","author":"C Giraudo","year":"2016","unstructured":"Giraudo C, Raderer M, Karanikas G et al (2016) 18F-fluorodeoxyglucose positron emission tomography\/magnetic resonance in lymphoma: comparison with 18F-fluorodeoxyglucose positron emission tomography\/computed tomography and with the addition of magnetic resonance diffusion-weighted imaging. Invest Radiol 51:163\u2013169","journal-title":"Invest Radiol"},{"key":"11213_CR12","doi-asserted-by":"publisher","first-page":"E323","DOI":"10.1148\/radiol.2021210436","volume":"300","author":"AS Becker","year":"2021","unstructured":"Becker AS, Perez-Johnston R, Chikarmane SA et al (2021) Multidisciplinary recommendations regarding post-vaccine adenopathy and radiologic imaging: Radiology Scientific Expert Panel. Radiology 300:E323\u2013E327","journal-title":"Radiology"},{"key":"11213_CR13","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1182\/bloodadvances.2020001579","volume":"4","author":"R Nakajima","year":"2020","unstructured":"Nakajima R, Moskowitz AJ, Michaud L et al (2020) Baseline FDG-PET\/CT detects bone marrow involvement in follicular lymphoma and provides relevant prognostic information. Blood Adv 4:1812\u20131823","journal-title":"Blood Adv"},{"key":"11213_CR14","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.3109\/10428194.2015.1030640","volume":"56","author":"SH Park","year":"2015","unstructured":"Park SH, Lee JJ, Kim HO et al (2015) 18F-Fluorodeoxyglucose (FDG)-positron emission tomography\/computed tomography in mucosa-associated lymphoid tissue lymphoma: variation in [18F]FDG avidity according to site involvement. Leuk Lymphoma 56:3288\u20133294","journal-title":"Leuk Lymphoma"},{"key":"11213_CR15","doi-asserted-by":"publisher","first-page":"vi144","DOI":"10.1093\/annonc\/mdt343","volume":"24","author":"E Zucca","year":"2013","unstructured":"Zucca E, Copie-Bergman C, Ricardi U et al (2013) Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi144\u2013vi148","journal-title":"Ann Oncol"},{"key":"11213_CR16","doi-asserted-by":"publisher","first-page":"e0239740","DOI":"10.1371\/journal.pone.0239740","volume":"15","author":"HH Lee","year":"2020","unstructured":"Lee HH, Cho SG, Lee IS et al (2020) Mantle cell lymphoma with gastrointestinal involvement and the role of endoscopic examinations. PLoS One 15:e0239740","journal-title":"PLoS One"},{"key":"11213_CR17","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","volume":"372","author":"J Radford","year":"2015","unstructured":"Radford J, Illidge T, Counsell N et al (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma. N Engl J Med 372:1598\u20131607","journal-title":"N Engl J Med"},{"key":"11213_CR18","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","volume":"1","author":"J Trotman","year":"2014","unstructured":"Trotman J, Luminari S, Boussetta S et al (2014) Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol 1:e17\u2013e27","journal-title":"Lancet Haematol"},{"key":"11213_CR19","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3390\/jpm13030445","volume":"13","author":"F Ibrahim","year":"2023","unstructured":"Ibrahim F, Gabelloni M, Faggioni L et al (2023) Are semiquantitative methods superior to Deauville scoring in the monitoring therapy response for pediatric Hodgkin lymphoma? J Pers Med 13:445","journal-title":"J Pers Med"},{"key":"11213_CR20","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2967\/jnumed.121.262205","volume":"63","author":"CN Burggraaff","year":"2022","unstructured":"Burggraaff CN, Eertink JJ, Lugtenburg PJ et al (2022) 18F-FDG PET improves baseline clinical predictors of response in diffuse large B-cell lymphoma: the HOVON-84 study. J Nucl Med 63:1001\u20131007","journal-title":"J Nucl Med"},{"key":"11213_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-024-01540-x","volume":"17","author":"D Leithner","year":"2024","unstructured":"Leithner D, Flynn JR, Devlin SM et al (2024) Conventional and novel [18F]FDG PET\/CT features as predictors of CAR-T cell therapy outcome in large B-cell lymphoma. J Hematol Oncol 17:21","journal-title":"J Hematol Oncol"},{"key":"11213_CR22","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1007\/s00259-022-06075-2","volume":"50","author":"M Winkelmann","year":"2023","unstructured":"Winkelmann M, Blumenberg V, Rejeski K et al (2023) Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy. Eur J Nucl Med Mol Imaging 50:1406\u20131413","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"11213_CR23","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1182\/blood.2019003277","volume":"135","author":"H Sch\u00f6der","year":"2020","unstructured":"Sch\u00f6der H, Polley MC, Knopp MV et al (2020) Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 clinical trial. Blood 135:2224\u20132234","journal-title":"Blood"},{"key":"11213_CR24","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1016\/S2589-7500(23)00203-0","volume":"6","author":"I H\u00e4ggstr\u00f6m","year":"2024","unstructured":"H\u00e4ggstr\u00f6m I, Leithner D, Alv\u00e9n J et al (2024) Deep learning for [18F]fluorodeoxyglucose-PET-CT classification in patients with lymphoma: a dual-centre retrospective analysis. Lancet Digit Health 6:e114\u2013e125","journal-title":"Lancet Digit Health"},{"key":"11213_CR25","doi-asserted-by":"publisher","unstructured":"Yousefirizi F, Klyuzhin IS, O JH et al (2024) TMTV-Net: fully automated total metabolic tumor volume segmentation in lymphoma PET\/CT images\u2014a multi-center generalizability analysis. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-024-06616-x","DOI":"10.1007\/s00259-024-06616-x"},{"key":"11213_CR26","doi-asserted-by":"publisher","first-page":"567","DOI":"10.7150\/thno.48620","volume":"11","author":"ME Mayerhoefer","year":"2021","unstructured":"Mayerhoefer ME, Raderer M, Lamm W et al (2021) CXCR4 PET imaging of mantle cell lymphoma using [68Ga]pentixafor: comparison with [18F]FDG-PET. Theranostics 11:567\u2013578","journal-title":"Theranostics"},{"key":"11213_CR27","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.7150\/thno.31032","volume":"9","author":"AR Haug","year":"2019","unstructured":"Haug AR, Leisser A, Wadsak W et al (2019) Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [68Ga]Ga-pentixafor-PET\/MRI. Theranostics 9:3653\u20133658","journal-title":"Theranostics"},{"key":"11213_CR28","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.2967\/jnumed.119.226134","volume":"60","author":"Y Luo","year":"2019","unstructured":"Luo Y, Cao X, Pan Q, Li J, Feng J, Li F (2019) 68Ga-pentixafor PET\/CT for imaging of chemokine receptor 4 expression in Waldenstr\u00f6m macroglobulinemia\/lymphoplasmacytic lymphoma: comparison to 18F-FDG PET\/CT. J Nucl Med 60:1724\u20131729","journal-title":"J Nucl Med"},{"key":"11213_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1097\/RLI.0000000000000469","volume":"53","author":"ME Mayerhoefer","year":"2018","unstructured":"Mayerhoefer ME, Jaeger U, Staber P et al (2018) [68Ga]Ga-pentixafor PET\/MRI for CXCR4 imaging of chronic lymphocytic leukemia: preliminary results. Invest Radiol 53:403\u2013408","journal-title":"Invest Radiol"},{"key":"11213_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1097\/RLU.0000000000003404","volume":"46","author":"AM Starzer","year":"2021","unstructured":"Starzer AM, Berghoff AS, Traub-Weidinger T et al (2021) Assessment of central nervous system lymphoma based on CXCR4 expression in vivo using 68Ga-pentixafor PET\/MRI. Clin Nucl Med 46:16\u201320","journal-title":"Clin Nucl Med"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11213-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-024-11213-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-024-11213-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T11:41:56Z","timestamp":1749814916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-024-11213-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["11213"],"URL":"https:\/\/doi.org\/10.1007\/s00330-024-11213-5","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"26 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Marius E. Mayerhoefer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was not required.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was not required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Study subjects or cohorts overlap"}},{"order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}